Abstract
γ-Secretase was first identified as a protease that cleaves amyloid precursor protein (APP) and produces Aβ peptides, which are thought to be pathogenic in Alzheimers disease (AD). However, the physiological functions of this enzyme remain to be clarified. In the canonical Notch signaling pathway, ligands bind to the extracellular domain of Notch and trigger sequential proteolytic cleavage. Finally, the intracellular domain (ICD) of Notch is released from the cell membrane by γ-secretase and translocates to the nucleus where it modulates gene expression through binding to transcription factors. Thus, γ-secretase plays a central regulatory role in the Notch signaling pathway. Recently, it was demonstrated that many type 1 transmembrane proteins, including APP and Notch, are substrates for γ-secretase, and the ICDs of these substrates are released from the cell membrane by γ-secretase. These processes are very similar to those that occur in Notch signaling. Thus, the common enzyme, γ-secretase, modulates proteolysis and the turnover of possible signaling molecules, suggesting that mechanisms similar to Notch signaling may contribute widely to γ-secretaseregulated signaling pathways, including APP signaling which leads to AD. Indeed, we have shown that ICD of APP induces dynamic changes in gene expression and neuron-specific apoptosis. Our findings suggest that APP signaling responds to the onset of AD. Here, we focus on γ-secretase-regulated signaling hypothesis and discuss the possibility that APP signaling may be closely correlated with the onset of AD.
Keywords: Alzheimer's disease, amyloid precursor protein, apoptosis, intracellular domain, Notch signaling, γ-secretase, the regulated intramembrane proteolysis mechanism, transmembrane proteins, Caenorhabditis elegans, Drosophila, metalloproteinases, TGF-β/Activin, PROTEASOME, Gene Ontology, Aβ oligomer
Current Psychopharmacology
Title: γ-Secretase-Regulated Signaling: Notch, APP, and Alzheimers Disease
Volume: 1
Author(s): Kohzo Nakayama, Hisashi Nagase, Chang-Sung Koh and Takeshi Ohkawara
Affiliation:
Keywords: Alzheimer's disease, amyloid precursor protein, apoptosis, intracellular domain, Notch signaling, γ-secretase, the regulated intramembrane proteolysis mechanism, transmembrane proteins, Caenorhabditis elegans, Drosophila, metalloproteinases, TGF-β/Activin, PROTEASOME, Gene Ontology, Aβ oligomer
Abstract: γ-Secretase was first identified as a protease that cleaves amyloid precursor protein (APP) and produces Aβ peptides, which are thought to be pathogenic in Alzheimers disease (AD). However, the physiological functions of this enzyme remain to be clarified. In the canonical Notch signaling pathway, ligands bind to the extracellular domain of Notch and trigger sequential proteolytic cleavage. Finally, the intracellular domain (ICD) of Notch is released from the cell membrane by γ-secretase and translocates to the nucleus where it modulates gene expression through binding to transcription factors. Thus, γ-secretase plays a central regulatory role in the Notch signaling pathway. Recently, it was demonstrated that many type 1 transmembrane proteins, including APP and Notch, are substrates for γ-secretase, and the ICDs of these substrates are released from the cell membrane by γ-secretase. These processes are very similar to those that occur in Notch signaling. Thus, the common enzyme, γ-secretase, modulates proteolysis and the turnover of possible signaling molecules, suggesting that mechanisms similar to Notch signaling may contribute widely to γ-secretaseregulated signaling pathways, including APP signaling which leads to AD. Indeed, we have shown that ICD of APP induces dynamic changes in gene expression and neuron-specific apoptosis. Our findings suggest that APP signaling responds to the onset of AD. Here, we focus on γ-secretase-regulated signaling hypothesis and discuss the possibility that APP signaling may be closely correlated with the onset of AD.
Export Options
About this article
Cite this article as:
Nakayama Kohzo, Nagase Hisashi, Koh Chang-Sung and Ohkawara Takeshi, γ-Secretase-Regulated Signaling: Notch, APP, and Alzheimers Disease, Current Psychopharmacology 2012; 1 (2) . https://dx.doi.org/10.2174/2211556011201020155
DOI https://dx.doi.org/10.2174/2211556011201020155 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitric Oxide and Schizophrenia: Present Knowledge and Emerging Concepts of Therapy
CNS & Neurological Disorders - Drug Targets Current Challenges to Overcome in the Management of Type 2 Diabetes Mellitus and Associated Neurological Disorders
CNS & Neurological Disorders - Drug Targets The Effects of Aqueous Extract of Apium Graveolens on Brain Tissues Oxidative Damage in Pentylenetetrazole-induced Seizures Model in Rat
Current Nutrition & Food Science Sensory-Dependent Knowledge in Young and Elderly Adults: Argument from the Cross-Modal Priming Effect
Current Aging Science The Gut-Brain Axis, Including the Microbiome, Leaky Gut and Bacterial Translocation: Mechanisms and Pathophysiological Role in Alzheimer’s Disease
Current Pharmaceutical Design Ages of Onset of Mood and Anxiety Disorders in Fragile X Premutation Carriers
Current Psychiatry Reviews Near-Infrared Spectroscopy (NIRS): A Non-Invasive In Vivo Methodology for Analysis of Brain Vascular and Metabolic Activities in Real Time in Rodents
Current Vascular Pharmacology Subject Index to Volume 1
Current Alzheimer Research Network Analysis of Depressive Symptomatology in Elderly Patients with Major Depressive Disorder
Current Psychiatry Research and Reviews Cerebral Angiogenesis and Expression of Angiogenic Factors in Aging Rats after Exercise
Current Neurovascular Research Modulation of Retinal Arteriolar Central Reflection by APOE Genotype
Current Alzheimer Research Leon Thal and the Alzheimers Disease Cooperative Study
Current Alzheimer Research Recent Developments in the Discovery of Novel Antipsychotic Agents Modualating Dopamine and Serotonin Receptors
Current Drug Targets β3-Adrenergic Receptors: Really Relevant Targets for Anti-Obesity Drugs?
Current Medicinal Chemistry - Central Nervous System Agents Miniaturization and Validation of the Ellmans Reaction Based Acetylcholinesterase Inhibitory Assay into 384-Well Plate Format and Screening of a Chemical Library
Combinatorial Chemistry & High Throughput Screening Biological Role of Formaldehyde, and Cycles Related to Methylation, Demethylation, and Formaldehyde Production
Mini-Reviews in Medicinal Chemistry Design, Synthesis, Characterization, Molecular Docking, ADME Properties and <i>In Vivo</i> Antipsychotic Activity of Aripiprazole Related Drugs Candidates
Letters in Drug Design & Discovery Aminochrome as New Preclinical Model to Find New Pharmacological Treatment that Stop the Development of Parkinson’s Disease
Current Medicinal Chemistry Silymarin Extends Lifespan and Reduces Proteotoxicity in C. elegans Alzheimer’s Model
CNS & Neurological Disorders - Drug Targets Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimers Disease
Current Medicinal Chemistry